An observational study in Cancer and / or Hematological Malignancy and Anthracycline-induced Cardiotoxicity, sponsored by South Tees Hospitals NHS Foundation Trust. Not yet recruiting at 6 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by South Tees Hospitals NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Hematologic Neoplasms with a site in United Kingdom — 24 open to participants now, 30 under way, 11 of them phase 3. Hematologic Neoplasms · United Kingdom.
Among the 72 studies in Hematologic Neoplasms with a site in United Kingdom, this one is one of 7 that started in 2026, is one of 9 observational ones, reaches primary completion later than 21 of the 29 other live ones, and was the 71st registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →24 of the 72 studies in Hematologic Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Surrey · Sites in United Kingdom
Ages 18+
Regeneron Pharmaceuticals · Sites in United Kingdom, Belgium
Ages 18+
CSL Behring · Sites in United Kingdom, United States, Belgium and 8 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United Kingdom, United States, Australia and 4 more countries
Ages 18+
Cancer Research UK · Sites in United Kingdom
Ages 1+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 34 · Phase 3 18
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 191 across 324 observational studies indexed under Hematologic Neoplasms.
Median enrollment 63 across the 63 interventional studies, 200 across the 9 observational. Of the 37 that completed or were terminated, 18 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 72 have an industry lead sponsor. The 10 most frequent:
South Tees Hospitals NHS Foundation Trust is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
South Tees Hospitals NHS Foundation Trust has 1 study filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Hematologic Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05391490University College, LondonAllogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies | 2027-02 |
| NCT05428969Faron Pharmaceuticals LtdA Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies | 2027-03 |
| NCT06645886Kumquat Biosciences Inc.A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | 2027-03 |
| NCT04068597CellCentric Ltd.Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | 2027-03-31 |
| NCT07463976The Royal Wolverhampton Hospitals NHS TrustvariaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 72 studies in Hematologic Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to collect information on how cancer treatment affects heart health. This will include collecting baseline medical information, storing blood samples, recording cancer treatment, and analysing heart scans across about 200 patients in several UK hospitals. We are aiming to: collect health information and store blood samples, alongside heart scans, to learn more about heart health after chemotherapy; improve understanding of why some patients develop heart problems, so that better tests, monitoring, and treatments can be developed in the future; build a UK-wide research group.
The overarching rationale of BHF-COLLATE is to establish the first phase of a UK multicentre cardio-oncology registry platform focused on anthracycline chemotherapy. Phase I is primarily designed as a feasibility and infrastructure building registry to establish a functioning multidisciplinary research network, harmonised study procedures, core imaging and biobanking workflows, and scalable data collection processes capable of supporting future national registry expansion and interventional clinical trials.
In parallel, exploratory clinical, imaging and biomarker analyses will improve understanding of the cardiovascular consequences of anthracycline chemotherapy in real-world clinical practice and help inform the design of future translational and interventional cardio-oncology studies.
Through the establishment of this first phase, and recruitment of a multicentre UK anthracycline registry, the study aims to comprehensively phenotype patients receiving anthracycline chemotherapy in order to:
establish a collaborative research network and platform to support future interventional clinical trials in cardio-oncology facilitate translational research through the biobanking of clinical samples linked to detailed baseline clinical assessments, cardiac imaging, and longitudinal follow-up data generate mechanistic insights to inform the design of future clinical trials and the development of improved diagnostic, risk-stratification, and surveillance strategies.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
This study's planned enrollment of 200 is close to the median of 191 across 324 observational studies indexed under Hematologic Neoplasms.
Browse Hematologic Neoplasms studies →South Tees Hospitals NHS Foundation Trust is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
Compared within Hematologic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Participants will be recruited from centres treating haemato-oncology and oncology patients and will be adult patients (18 years and above) who are due to receive anthracycline-based chemotherapy for their cancer* and provide written informed consent prior to study participation.
*Participants are likely to be those being treated for breast cancer, lymphoma and sarcoma. Where patients need an expedited start to their anthracycline-based chemotherapy regimen for urgent clinical reasons that precludes enrolment prior to the start of cycle 1 (e.g. patients with NHL where treatment must start within a couple of days), they can still be included as long as consent, baseline assessments and eligibility is confirmed prior to the start of cycle 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with confirmed solid organ or haematological malignancy; Adults aged 18 years or older; Planned to receive anthracycline chemotherapy; or prior to the start of the second cycle of anthracycline chemotherapy for those who required an urgent start to their chemotherapy for clinical reasons.
Number of participants recruited
Recruitment of 200 participants with ≥75% of patients at medium or higher HFA-ICOS score
Time frame: 16 months
Cardiac function
Cardiac function assessed by core lab artificial intelligence (AI) enabled echocardiogram via measurement of left ventricular ejection fraction (LVEF) in (%).
Time frame: 12 months
Cardiac function
Cardiac function assessed by core lab artificial intelligence (AI) enabled echocardiogram via measurement of global longitudinal strain (GLS) in a negative percentage (%).
Time frame: 12 months
Cancer outcomes
Cancer outcomes - Entries recorded in the patient's medical records including cancer relapse/recurrence and diagnosis.
Time frame: 12 months
Cancer outcomes
Cancer treatment completeness including number of cycles whether dosage was changed/delayed/reduced/discontinued - total dose of anthracycline received in (mg/m²) of body surface area.
Time frame: 12 months
Cardiovascular Outcomes
1Cardiovascular outcomes including cancer therapy related cardiac dysfunction (CTRCD). Entries as recorded in the patients' medical records including: * new diagnoses of heart failure * new diagnoses of atrial fibrillation * new diagnoses of myocardial infarction * new diagnoses of stroke or Transient Ischaemic Attack (TIA) * new diagnoses of deep vein thrombosis (DVT) * new diagnoses of Pulmonary Embolous (PE).
Time frame: 12 months
Quality of Life
Measurement of health-related quality of life of cancer patients through completion of EORTC-QLQ-C30 questionnaire. Most items use a 4-point scale ranging from 1 ("Not at all") to 4 ("Very much"); the global health/QoL items towards the end of the questionnaire use a 7-point scale from 1 ("Very poor") to 7 ("Excellent"). Overall scores are calculated by adding up the numerical response values in a section and calculating an average score. This score is then converted to a 0-100 score using the scoring manual. A higher score means a better level of functioning or higher quality of life, a lower score signifies lower QoL.
Time frame: 12 months
Quality of Life
Measurement of patient-reported Quality of Life assessments through completion of the EQ-5D-5L questionnaire.
Time frame: 12 months
Biobanking and data collection
To facilitate translational research through the biobanking of clinical samples (including biomarkers and genomics)
Time frame: 12 months
Plan to share: Yes — We are committed to sharing samples and de-identified individual level data, where a rigorous research question may be answered. Appropriate data and material sharing agreements and Data Protection Impact Assesments (DPIA)s will be put in place where required. The research team including the Chief Investigator and Sponsor will consider proposals from researchers as long as there is no constraint due to: Ethical approval and informed consent The request does not require the data/samples prior to publication of key findings or appropriate agreements are able to be place to protect the original work. The request for data and/or samples does not extend beyond that which is needed to answer the specific research question. Overall responsibility for data collection lies with the Chief Investigator. Study data will be handled, computerised and stored in accordance with the Data Protection Act 2018, and local policy.
Supporting information: Study protocol, Clinical study report
Time frame: After primary and secondary analyses have occured
Access criteria: The research team including the Chief Investigator and Sponsor will consider proposals from researchers as long as there are no constraints as described earlier.
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Nov 2029, 38 months later.
Of 164 non-industry observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's planned 38 months is below that.
Counting every sponsor, half of 186 studies reached it within 74 months; a quarter within 34 and three quarters within 322.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
South Tees Hospitals NHS Foundation Trust